Journal Home > Volume 2 , Issue 2
Cancer Innovation 2023, 2(2): 131-139 https://doi.org/10.1002/cai2.66
Review | Open Access | Issue | Published: 08 April 2023

Advances in the treatment of solid tumors in children and adolescents

Show Author's Information Jing Tian1,  Jiayu Wang1,  Sidan Li2( )
Beijing Key Laboratory of Pediatric Hematology Oncology, Key Laboratory of Major Diseases in Children, National Key Discipline of Pediatrics (Capital Medical University), Ministry of Education, Beijing Children's Hospital, Hematology Center, National Center for Children's Health, Capital Medical University, Beijing, China
Department of Medical Oncology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Jing Tian and Jiayu Wang contributed equally to this study and shared the first authorship.

Keywords:
treatment, tumor, immune checkpoint inhibitors, children and adolescents
Cite this article:
Tian J, Wang J, Li S. Advances in the treatment of solid tumors in children and adolescents. Cancer Innovation, 2023, 2(2): 131-139. https://doi.org/10.1002/cai2.66
Download citation
EndNote(RIS)
BibTeX

373

Views

19

Downloads

Citations

1

Crossref

N/A

WoS

1

Scopus

N/A

CSCD

Abstract Full text About this article

Tumor is one of the leading causes of death in children (0 to 14‐year‐old) and adolescents (15 to 19‐year‐old) worldwide. Unlike adult tumors, childhood and adolescent tumors are unique in their type, molecular characteristics, and pathogenesis, and their treatment involves many challenges. In recent years, with the development of a large number of clinical studies, the survival rate of children and adolescents with tumors has improved significantly. The extensive research and application of optimized treatment regimens and new targeted drugs have led to new hope for the treatment of childhood and adolescent tumors. This article reviews the clinical and basic research and treatment of childhood and adolescent tumors and provides new ideas for the future development of precise treatment of childhood and adolescent tumors.


menu
Abstract
Full text
Outline
About this article

Advances in the treatment of solid tumors in children and adolescents

Show Author's information Jing Tian1, Jiayu Wang1, Sidan Li2( )
Beijing Key Laboratory of Pediatric Hematology Oncology, Key Laboratory of Major Diseases in Children, National Key Discipline of Pediatrics (Capital Medical University), Ministry of Education, Beijing Children's Hospital, Hematology Center, National Center for Children's Health, Capital Medical University, Beijing, China
Department of Medical Oncology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Jing Tian and Jiayu Wang contributed equally to this study and shared the first authorship.

Abstract

Tumor is one of the leading causes of death in children (0 to 14‐year‐old) and adolescents (15 to 19‐year‐old) worldwide. Unlike adult tumors, childhood and adolescent tumors are unique in their type, molecular characteristics, and pathogenesis, and their treatment involves many challenges. In recent years, with the development of a large number of clinical studies, the survival rate of children and adolescents with tumors has improved significantly. The extensive research and application of optimized treatment regimens and new targeted drugs have led to new hope for the treatment of childhood and adolescent tumors. This article reviews the clinical and basic research and treatment of childhood and adolescent tumors and provides new ideas for the future development of precise treatment of childhood and adolescent tumors.

Keywords: treatment, tumor, immune checkpoint inhibitors, children and adolescents

References(48)

1

Pfister SM, Reyes‐Múgica M, Chan JKC, Hasle H, Lazar AJ, Rossi S, et al. A summary of the inaugural WHO classification of pediatric tumors: transitioning from the optical into the molecular era. Cancer Discov. 2022;12(2): 331–55. https://doi.org/10.1158/2159-8290.CD-21-1094
DOI Google Scholar
2

Ni X, Li Z, Li X, Zhang X, Bai G, Liu Y, et al. Socioeconomic inequalities in cancer incidence and access to health services among children and adolescents in China: a cross‐sectional study. Lancet. 2022;400(10357): 1020–32. https://doi.org/10.1016/S0140-6736(22)01541-0
DOI Google Scholar
3

Chang WH, Katsoulis M, Tan YY, Mueller SH, Green K, Lai AG. Late effects of cancer in children, teenagers and young adults: population‐based study on the burden of 183 conditions, in‐patient and critical care admissions and years of life lost. Lancet Reg Health‐Europe. 2022;12:100248. https://doi.org/10.1016/j.lanepe.2021.100248
DOI Google Scholar
4

Castellino SM, Pei Q, Parsons SK, Hodgson D, McCarten K, Horton T, et al. Brentuximab vedotin with chemotherapy in pediatric high‐risk Hodgkin's lymphoma. N Engl J Med. 2022;387(18): 1649–60. https://doi.org/10.1056/NEJMoa2206660
DOI Google Scholar
5

Mauz‐Körholz C, Landman‐Parker J, Balwierz W, Ammann RA, Anderson RA, Attarbaschi A, et al. Response‐adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate‐stage and advanced‐stage classical Hodgkin lymphoma (EuroNet‐PHL‐C1): a titration study with an open‐label, embedded, multinational, non‐inferiority, randomised controlled trial. Lancet Oncol. 2022;23(1): 125–37. https://doi.org/10.1016/S1470-2045(21)00470-8
DOI Google Scholar
6

Garaventa A, Poetschger U, Valteau‐Couanet D, Luksch R, Castel V, Elliott M, et al. Randomized trial of two induction therapy regimens for high‐risk neuroblastoma: HR‐NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study. J Clin Oncol. 2021;39(23): 2552–63. https://doi.org/10.1200/JCO.20.03144
DOI Google Scholar
7

Bisogno G, Jenney M, Bergeron C, Gallego Melcón S, Ferrari A, Oberlin O, et al. Addition of dose‐intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open‐label, randomised controlled, phase 3 trial. Lancet Oncol. 2018;19(8): 1061–71. https://doi.org/10.1016/S1470-2045(18)30337-1
DOI Google Scholar
8

Deyell RJ, Wu B, Rassekh SR, Tu D, Samson Y, Fleming A, et al. Phase I study of vinblastine and temsirolimus in pediatric patients with recurrent or refractory solid tumors: Canadian Cancer Trials Group Study IND.218. Pediatr Blood Cancer. 2019;66(3): e27540. https://doi.org/10.1002/pbc.27540
DOI Google Scholar
9

Mascarenhas L, Chi YY, Hingorani P, Anderson JR, Lyden ER, Rodeberg DA, et al. Randomized phase Ⅱ trial of bevacizumab or temsirolimus in combination with chemotherapy for first relapse rhabdomyosarcoma: a report from the children's oncology group. J Clin Oncol. 2019;37(31): 2866–74. https://doi.org/10.1200/JCO.19.00576
DOI Google Scholar
10

Defachelles AS, Bogart E, Casanova M, Merks J, Bisogno G, Calareso G, et al. Randomized phase Ⅱ trial of vincristine‐irinotecan with or without temozolomide, in children and adults with relapsed or refractory rhabdomyosarcoma: a European Paediatric Soft Tissue Sarcoma Study Group and innovative therapies for children with cancer trial. J Clin Oncol. 2021;39(27): 2979–90. https://doi.org/10.1200/JCO.21.00124
DOI Google Scholar
11

Mora J, Modak S. Nivolumab in paediatric cancer: children are not little adults. Lancet Oncol. 2020;21(4): 474–6. https://doi.org/10.1016/S1470-2045(20)30086-3
DOI Google Scholar
12

Majzner RG, Simon JS, Grosso JF, Martinez D, Pawel BR, Santi M, et al. Assessment of programmed death‐ligand 1 expression and tumor‐associated immune cells in pediatric cancer tissues: PD‐L1 & immune cells in pediatric cancer. Cancer. 2017;123(19): 3807–15. https://doi.org/10.1002/cncr.30724
DOI Google Scholar
13

Davis KL, Fox E, Merchant MS, Reid JM, Kudgus RA, Liu X, et al. Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open‐label, single‐arm, phase 1–2 trial. Lancet Oncol. 2020;21(4): 541–50. https://doi.org/10.1016/S1470-2045(20)30023-1
DOI Google Scholar
14

Pasqualini C, Rubino J, Brard C, Cassard L, André N, Rondof W, et al. Phase Ⅱ and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: arm G of AcSé‐ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium. Eur J Cancer. 2021;150:53–62. https://doi.org/10.1016/j.ejca.2021.03.032
DOI Google Scholar
15

Geoerger B, Kang HJ, Yalon‐Oren M, Marshall LV, Vezina C, Pappo A, et al. Pembrolizumab in paediatric patients with advanced melanoma or a PD‐L1‐positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE‐051): interim analysis of an open‐label, single‐arm, phase 1–2 trial. Lancet Oncol. 2020;21(1): 121–33. https://doi.org/10.1016/S1470-2045(19)30671-0
DOI Google Scholar
16

Geoerger B, Zwaan CM, Marshall LV, Michon J, Bourdeaut F, Casanova M, et al. Atezolizumab for children and young adults with previously treated solid tumours, non‐Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1–2 study. Lancet Oncol. 2020;21(1): 134–44. https://doi.org/10.1016/S1470-2045(19)30693-X
DOI Google Scholar
17

Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA‐4 blockade. Science. 1996;271(5256): 1734–6. https://doi.org/10.1126/science.271.5256.1734
DOI Google Scholar
18

Merchant MS, Wright M, Baird K, Wexler LH, Rodriguez‐Galindo C, Bernstein D, et al. Phase I clinical trial of ipilimumab in pediatric patients with advanced solid tumors. Clin Cancer Res. 2016;22(6): 1364–70. https://doi.org/10.1158/1078-0432.CCR-15-0491
DOI Google Scholar
19

Geoerger B, Bergeron C, Gore L, Sender L, Dunkel IJ, Herzog C, et al. Phase Ⅱ study of ipilimumab in adolescents with unresectable stage Ⅲ or Ⅳ malignant melanoma. Eur J Cancer. 2017;86:358–63. https://doi.org/10.1016/j.ejca.2017.09.032
DOI Google Scholar
20

Davis KL, Fox E, Isikwei E, Reid JM, Liu X, Minard CG, et al. A phase Ⅰ/Ⅱ trial of nivolumab plus ipilimumab in children and young adults with relapsed/refractory solid tumors: a Children's Oncology Group Study ADVL1412. Clin Cancer Res. 2022;28(23): 5088–97. https://doi.org/10.1158/1078-0432.CCR-22-2164
DOI Google Scholar
21

Furman WL, Mccarville B, Shulkin BL, Davidoff A, Krasin M, Hsu CW, et al. Improved outcome in children with newly diagnosed high‐risk neuroblastoma treated with chemoimmunotherapy: updated results of a phase Ⅱ study using hu14.18K322A. J Clin Oncol. 2022;40(4): 335–44. https://doi.org/10.1200/JCO.21.01375
DOI Google Scholar
22

Mora J, Castañeda A, Gorostegui M, et al. Naxitamab combined with granulocyte‐macrophage colony‐stimulating factor as consolidation for high‐risk neuroblastoma patients in complete remission. Pediatr Blood Cancer. 2021;68(10): e29121. https://doi.org/10.1002/pbc.29121
DOI Google Scholar
23

Nguyen R, Zhang X, Sun M, Abbas S, Seibert C, Kelly MC, et al. Anti‐GD2 antibodies conjugated to IL15 and IL21 mediate potent antitumor cytotoxicity against neuroblastoma. Clin Cancer Res. 2022;28(17): 3785–96. https://doi.org/10.1158/1078-0432.CCR-22-0717
DOI Google Scholar
24

Mabe NW, Huang M, Dalton GN, Alexe G, Schaefer DA, Geraghty AC, et al. Transition to a mesenchymal state in neuroblastoma confers resistance to anti‐GD2 antibody via reduced expression of ST8SIA1. Nat Cancer. 2022;3(8): 976–93. https://doi.org/10.1038/s43018-022-00405-x
DOI Google Scholar
25

Cheung IY, Cheung NKV, Modak S, Mauguen A, Feng Y, Basu E, et al. Survival impact of anti‐GD2 antibody response in a phase Ⅱ ganglioside vaccine trial among patients with high‐risk neuroblastoma with prior disease progression. J Clin Oncol. 2021;39(3): 215–26. https://doi.org/10.1200/JCO.20.01892
DOI Google Scholar
26

Cheung IY, Cheung NKV, Modak S, Mauguen A, Feng Y, Basu E, et al. Survival impact of anti‐GD2 antibody response in a phase Ⅱ ganglioside vaccine trial among patients with high‐risk neuroblastoma with prior disease progression. J Clin Oncol. 2021;39(3): 215–26. https://doi.org/10.1200/JCO.20.01892
DOI Google Scholar
27

Kendsersky NM, Lindsay J, Kolb EA, Smith MA, Teicher BA, Erickson SW, et al. The B7‐H3–targeting antibody–drug conjugate m276‐SL‐PBD is potently effective against pediatric cancer preclinical solid tumor models. Clin Cancer Res. 2021;27(10): 2938–46. https://doi.org/10.1158/1078-0432.CCR-20-4221
DOI Google Scholar
28

Hong DS, Dubois SG, Kummar S, Farago AF, Albert CM, Rohrberg KS, et al. Larotrectinib in patients with TRK fusion‐positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol. 2020;21(4): 531–40. https://doi.org/10.1016/S1470-2045(19)30856-3
DOI Google Scholar
29

Freedman A, Jacobsen E. Follicular lymphoma: 2020 update on diagnosis and management. Am J Hematol. 2020;95(3): 316–27. https://doi.org/10.1002/ajh.25696
DOI Google Scholar
30

Wobser M, Voigt H, Eggert AO, Houben R, Kauczok CS, Bröcker EB, et al. Bcl‐2 expression in rituximab refractory cutaneous B‐cell lymphoma. Br J Cancer. 2007;96(10): 1540–3. https://doi.org/10.1038/sj.bjc.6603762
DOI Google Scholar
31

Monni O, Franssila K, Joensuu H, Knuutila S. BCL2 overexpression in diffuse large B‐cell lymphoma. Leuk Lymphoma. 1999;34(1–2): 45–52. https://doi.org/10.3109/10428199909083379
DOI Google Scholar
32

Xi YF, Wang GP, Li Y, Wang JF, Sun RF. Correlation of Bcl‐2 with immunological subtype and prognosis in diffuse large B‐cell lymphoma. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi. 2010;31(1): 34–7. https://pubmed.ncbi.nlm.nih.gov/20302777/
Google Scholar
33

Johnson NA, Slack GW, Savage KJ, Connors JM, Ben‐Neriah S, Rogic S, et al. Concurrent expression of MYC and BCL2 in diffuse large B‐cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30(28): 3452–9. https://doi.org/10.1200/JCO.2011.41.0985
DOI Google Scholar
34

Lorsbach RB, Shay‐Seymore D, Moore J, Banks PM, Hasserjian RP, Sandlund JT, et al. Clinicopathologic analysis of follicular lymphoma occurring in children. Blood. 2002;99(6): 1959–64. https://doi.org/10.1182/blood.V99.6.1959
DOI Google Scholar
35

Frost M, Newell J, Lones MA, Tripp SR, Cairo MS, Perkins SL. Comparative immunohistochemical analysis of pediatric burkitt lymphoma and diffuse large B‐cell lymphoma. Am J Clin Path. 2004;121(3): 384–92. https://doi.org/10.1309/8WYNVUTGV9RPHUQH
DOI Google Scholar
36

Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT‐199, a potent and selective BCL‐2 inhibitor, achieves antitumor activity while sparing platelets. Nature Med. 2013;19(2): 202–8. https://doi.org/10.1038/nm.3048
DOI Google Scholar
37

Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, et al. Phase I first‐in‐human study of venetoclax in patients with relapsed or refractory non‐Hodgkin lymphoma. J Clin Oncol. 2017;35(8): 826–33. https://doi.org/10.1200/JCO.2016.70.4320
DOI Google Scholar
38

Griffin TC, Weitzman S, Weinstein H, Chang M, Cairo M, Hutchison R, et al. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B‐cell (CD20+) non‐Hodgkin lymphoma and mature B‐cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2009;52(2): 177–81. https://doi.org/10.1002/pbc.21753
DOI Google Scholar
39

Gibson A, Trabal A, Mccall D, Khazal S, Toepfer L, Bell DH, et al. Venetoclax for children and adolescents with acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancers. 2021;14(1): 150. https://doi.org/10.3390/cancers14010150
DOI Google Scholar
40

Pullarkat VA, Lacayo NJ, Jabbour E, Rubnitz JE, Bajel A, Laetsch TW, et al. Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancer Discov. 2021;11(6): 1440–53. https://doi.org/10.1158/2159-8290.CD-20-1465
DOI Google Scholar
41

Szydzik J, Lind DE, Arefin B, Kurhe Y, Umapathy G, Siaw JT, et al. ATR inhibition enables complete tumour regression in ALK‐driven NB mouse models. Nat Commun. 2021;12(1): 6813. https://doi.org/10.1038/s41467-021-27057-2
DOI Google Scholar
42

Wierdl M, Tsurkan L, Chi L, Hatfield MJ, Tollemar V, Bradley C, et al. Targeting ALK in pediatric RMS does not induce antitumor activity in vivo. Cancer Chemother Pharmacol. 2018;82(2): 251–63. https://doi.org/10.1007/s00280-018-3615-7
DOI Google Scholar
43

Fukano R, Mori T, Sekimizu M, Choi I, Kada A, Saito AM, et al. Alectinib for relapsed or refractory anaplastic lymphoma kinase‐positive anaplastic large cell lymphoma: an open‐label phase Ⅱ trial. Cancer Sci. 2020;111(12): 4540–7. https://doi.org/10.1111/cas.14671
DOI Google Scholar
44

Desai AV, Robinson GW, Gauvain K, Basu EM, Macy ME, Maese L, et al. Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or AL Kaberrations (STARTRK‐NG). Neuro‐Oncol. 2022;24(10): 1776–89. https://doi.org/10.1093/neuonc/noac087
DOI Google Scholar
45

Singh S, Abu‐Zaid A, Jin H, Fang J, Wu Q, Wang T, et al. Targeting KDM4 for treating PAX3‐FOXO1–driven alveolar rhabdomyosarcoma. Sci Transl Med. 2022;14(653): eabq2096. https://doi.org/10.1126/scitranslmed.abq2096
DOI Google Scholar
46

Tian M, Cheuk AT, Wei JS, Abdelmaksoud A, Chou H‐C, Milewski D, et al. An optimized bicistronic chimeric antigen receptor against GPC2 or CD276 overcomes heterogeneous expression in neuroblastoma. J Clin Invest. 2022;132(16): e155621. https://doi.org/10.1172/JCI155621
DOI Google Scholar
47

Durbin AD, Wang T, Wimalasena VK, Zimmerman MW, Li D, Dharia NV, et al. EP300 selectively controls the enhancer landscape of MYCN‐amplified neuroblastoma. Cancer Discov. 2022;12(3): 730–51. https://doi.org/10.1158/2159-8290.CD-21-0385
DOI Google Scholar
48

Jiang J, Wang R, Yang L, Sha Y, Zhao S, Guo J, et al. IL‐11Rα‐targeted nanostrategy empowers chemotherapy of relapsed and patient‐derived osteosarcoma. J Controlled Release. 2022;350:460–70. https://doi.org/10.1016/j.jconrel.2022.08.048
DOI Google Scholar
Publication history
Copyright
Acknowledgements
Rights and permissions

Publication history

Received: 12 January 2023
Accepted: 13 March 2023
Published: 08 April 2023
Issue date: April 2023

Copyright

© 2023 The Authors.

Acknowledgements

ACKNOWLEDGMENTS

None.

Rights and permissions

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Return